In this article/podcast from KevinMD.com, the author fears that after decades of progress in detecting, treating, and preventing many types of cancers, this nation could face a “cancer pandemic” in the next ten years as a result of this delay in routine screenings. These missed cancer screenings will likely result in delayed cancer diagnoses, recurrence […]
In this Celebrity Diagnosis opinion piece from MedPage Today, the author discusses the legendary guitarist’s original throat cancer diagnosis, its possible causes – including Eddie’s own theory — and how it spread to other parts of his head and neck. The article also examines the risks, symptoms, and treatment options of head and neck cancers.
In this study from the Journal of Clinical Oncology, the authors attempted to characterize the cancer-associated risk factors for COVID-19 adverse outcomes. Their hypothesis was that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. Were they right?
The study looked at cancer survivors aged 65 or older from the SEER-Medicare database; survivors were diagnosed with cancer between 2000 and 2012. Claims from 2007 to 2013 were used to estimate costs by cancer site, phases of care, and stage at diagnosis.
Published in JCO Clinical Practice and developed by a working group of 7 experts in oncology pharmacy practice, the guidelines outline 26 recommendations covering the use of anticancer medications, from proper staff hygiene and safety to how to conduct clinical trials.
In addition to reducing pack-years history of smoking, the recommendation calls for annual screening for lung cancer at age 50 years instead of age 55 years, an update of the U.S. Preventive Services Task Force (USPSTF) guidance on lung cancer screening issued 7 years ago.
In this podcast, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.
The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.
The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.
After tobacco use and excess body weight, alcohol consumption is the third major modifiable cancer risk factor. In its latest guidelines, the American Cancer Society has tightened its grip on its recommendations, basically telling people not to drink alcohol at all if they want to prevent cancer risk.